IQVIA Holdings Inc.
IQV Healthcare Medical - Diagnostics & Research NYSE
$174.45
$-4.05 (-2.27%)
Open: $178.89 | High: $179.65 | Low: $173.93 | Prev Close: $178.50
Market Cap: $29.71B
Volume: 734K | Avg: 2.0M
Last updated: March 06, 2026 at 06:03 PMFeatured In
This stock appears in the following dashboards:
Options Activity for IQV
Options Screener Data
| Type | Strike | Expiration | Premium | Premium Yield | Call Vol | Put Vol | P/C Ratio | Rating |
|---|---|---|---|---|---|---|---|---|
| N/A | $N/A | N/A | $N/A | N/A% | N/A | N/A | N/A | N/A/10 |
Puts/Calls Activity
| Type | Strike | Expiration | Premium | Volume | ROI % | Breakeven | Delta |
|---|---|---|---|---|---|---|---|
| N/A | $N/A | N/A | $N/A | N/A | N/A% | $N/A | N/A |
Investment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 425
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 22.25 |
| P/B Ratio | 4.56 |
| P/S Ratio | 1.82 |
| EPS | $7.84 |
| Beta | 1.41 |
| Shares Outstanding | 170.30M |
| 52-Week High | $247.05 |
| 52-Week Low | $134.65 |
| SMA 50 | $209.18 |
| SMA 200 | $193.93 |
| Next Earnings | May 05, 2026 04:00 AM ET |
Financial Ratios
| Gross Margin | 26.3% |
| Operating Margin | 14.0% |
| Net Margin | 8.3% |
| ROE | 22.3% |
| ROA | 4.5% |
| Debt/Equity | 2.49 |
| Current Ratio | 0.75 |
| Quick Ratio | 0.75 |
Balance Sheet
| Total Assets | $29.94B |
| Total Liabilities | $23.31B |
| Total Equity | $6.50B |
|
|
|
| Cash | $1.98B |
| Total Debt | $16.17B |
| Net Debt | $14.19B |
Income Statement
| Revenue | $16.31B |
| Gross Profit | $4.29B |
| Operating Income | $2.29B |
| Net Income | $1.36B |
|
|
|
| EBITDA | $3.46B |
| Revenue/Share | $95.94 |
Cash Flow
| Operating CF | $2.65B |
| CapEx | $603.00M |
| Free Cash Flow | $2.05B |
|
|
|
| Book Value/Share | $39.00 |
| Tangible Book/Share | $-87.93 |
| Equity/Share | $38.25 |
Technical Indicators
| RSI (14) | 55.09 Neutral |
| MACD |
-9.40
Signal: -12.68
|
| Volatility | 56.96% |
| Trading Signal | Bullish |
Performance & Returns
| 1 Year | +21.53% |
| Sharpe Ratio | 0.67 Fair |
| Volatility (Ann.) | 40.3% High Risk |
| IQV (1Y) | +21.53% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | +8.5% |
Sector Comparison (Healthcare)
| Metric | IQV | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 22.25 | 27.76 | 38% |
| P/B Ratio | 4.56 | -19.61 | 64% |
| ROE (%) | 22.28% | -9.71% | 72% |
| Net Margin (%) | 8.34% | 9.34% | 34% |
| Stock Score | 425 | 546.0 | 6% |
| 1Y Return (%) | +21.53 % | +7.88 % | 65% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IQV | $174.45 | $175.70 | $172.12 | $169.22 | $207.62 | $193.95 | 55.09 | -9.40 | 56.96% | 467031 | Neutral | Bullish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the IQV stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| IQV | IQVIA Holdings Inc. (IQV) Presents at Barclays 28th Annual Global Healthcare Conference Transcript | Neutral | seekingalpha.com | Read More |
| IQV | IQVIA Holdings Inc. (IQV) Presents at Leerink Global Healthcare Conference 2026 Transcript | Neutral | seekingalpha.com | Read More |
| IQV | IQVIA Holdings Inc. $IQV Shares Bought by Elo Mutual Pension Insurance Co | Neutral | defenseworld.net | Read More |
| IQV | DNB Asset Management AS Cuts Stock Position in IQVIA Holdings Inc. $IQV | Neutral | defenseworld.net | Read More |
| IQV | IQVIA Holdings: Still Exceeding Expectations As A Stealth Compounder | Neutral | seekingalpha.com | Read More |
Recent Insider Trading
No recent insider trading data available for IQV
Company Information
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
| CEO | Ari Bousbib |
| Employees | 89000 |
| Country | US |
| IPO Date | 2013-05-09 |
| Exchange | NYSE |
| Website | https://www.iqvia.com |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
Similar Stocks (Healthcare - Medical - Diagnostics & Research)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category